New Drug ==> CMet (?) for Papillary RCC
Good news kids! I had my second scan since I began Votrient in August 2012 and the lung mets and lymph node are stable. My November scans showed shrinkage and stability, this February scan showed stability. I will post the details in a thread from one of our previous discussions.
Okay, all of that is good and fine, but my Onc said he is an investigator for a new drug that is more specific to the papillary type of RCC, and it is in Phase I trials. I was still as happy as a kid making snow angels after he told me I was stable, AND he said we would stick to Votrient for as long as it works, so I am not completely clear on the new drug. I’ll just tell you what I THINK he said:
The new drug is either called CMet, or it targets CMET (or both), and it addresses the specific pathways of papillary RCC. A tumor sample (not a new sample, but an existing sample if you previously had a biopsy) would be sent for testing to determine if it is the type to respond to the drug. I did at least have the level of consciousness to ask about a new biopsy, since I never-ever want another biopsy.
Anyway, it is good to know there is another option if the Votrient does not work for those of us with the papillary type, and good for those of us who need to know they are still working toward specific treatments for RCC.
Comments
-
All good!!!
The drug will be foretinib, a cMET inhibitor
http://link.springer.com/article/10.1007/s11912-013-0299-3
but, meantime,stick with me kid on Votrient. Can't say how delighted I am to hear your news. It seems as though Votrient may be very useful for rarer sub-types - you're pRCC and I'm sarcomatoid chRCC. Here's to both of us (and everyone else too, of course!). Handy, too - you've just reminded me to go take my Votrient.
0 -
(Amended)
---
0 -
I took a lookTexas_wedge said:All good!!!
The drug will be foretinib, a cMET inhibitor
http://link.springer.com/article/10.1007/s11912-013-0299-3
but, meantime,stick with me kid on Votrient. Can't say how delighted I am to hear your news. It seems as though Votrient may be very useful for rarer sub-types - you're pRCC and I'm sarcomatoid chRCC. Here's to both of us (and everyone else too, of course!). Handy, too - you've just reminded me to go take my Votrient.
I read a little about foretinib and I think I actually like Votrient. Can't give it a thumbs up or down, but I like to stick with the known versus the unknown....
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.8K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 397 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 792 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 61 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 539 Sarcoma
- 730 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards